Combination regimens with dual specificity inhibitors
| Target . | Compound . | Combination regimens . | Effects . | Clinical trials (phase) . | References . | |
|---|---|---|---|---|---|---|
| In vitro . | In vivo . | |||||
| PI3K/mTOR | PI-103 | Nutlin-3 (MDM2-I) | + | − | 158 | |
| STI-571 (Bcr-Abl-TKI) | + | − | 142 | |||
| Arsenic disulfide | + | − | 174 | |||
| Vincristine (CT) | + | − | 126 | |||
| Fludarabine (CT) | + | − | 76 | |||
| PI3K/mTOR | NVP-BEZ235 | CT | + | − | 124 | |
| PI3K/PDK1 | BAG956 | STI-571 (Bcr-Abl-TKI) | + | + | 121 | |
| Rapamycin/RAD-001 | + | − | 121 | |||
| PKC412 (Flt3 TKI) | + | + | 121 | |||
| Target . | Compound . | Combination regimens . | Effects . | Clinical trials (phase) . | References . | |
|---|---|---|---|---|---|---|
| In vitro . | In vivo . | |||||
| PI3K/mTOR | PI-103 | Nutlin-3 (MDM2-I) | + | − | 158 | |
| STI-571 (Bcr-Abl-TKI) | + | − | 142 | |||
| Arsenic disulfide | + | − | 174 | |||
| Vincristine (CT) | + | − | 126 | |||
| Fludarabine (CT) | + | − | 76 | |||
| PI3K/mTOR | NVP-BEZ235 | CT | + | − | 124 | |
| PI3K/PDK1 | BAG956 | STI-571 (Bcr-Abl-TKI) | + | + | 121 | |
| Rapamycin/RAD-001 | + | − | 121 | |||
| PKC412 (Flt3 TKI) | + | + | 121 | |||
I indicates inhibitor; TKI, tyrosine kinase inhibitor; and CT, chemotherapy.